Articles tagged "Immunosuppression"

2019 American Transplant Congress
Bespoke Immunosuppression: Prolonging Transplant Survival through Enhanced T-cell Activation Induced Cell Death
R. Costello¹, R. J. Ingram¹, D. Longley², J. McDaid³
¹WWIEM, QUB, Belfast, United Kingdom, ²CCRCB, QUB, Belfast, United Kingdom, ³Renal Transplantation, Belfast City Hospital, Belfast, United Kingdom
*Purpose: We aim to develop donor-specific immunosuppression by inhibiting T-cell cellular FLICE like inhibitory protein (c-FLIP). Our current work focuses on clinically relevant pharmacological inhibitors…
2019 American Transplant Congress
Immunosuppression Reduction after Diagnosis of Sustained BK Viremia and the Risk of Allograft Rejection, Allograft Loss and Mortality
F. A. Al Dhufairi¹, M. Shokoohi², A. M. Jevnikar¹, A. A. House¹, D. Kumar³, S. M. Hosseini-Moghaddam¹
¹Department of Medicine, Western University, London Health Sciences Centre, London, ON, Canada, ²Epidemiology and Biostatistics, Western University, London, ON, Canada, ³Department of Medicine, University Of Toronto, University Health Network, Toronto, ON, Canada
*Purpose: BK viremia increases the risk of allograft loss after renal transplantation. Current guidelines recommend immunosuppression reduction (IsR) after the diagnosis of BK viremia. The…
2019 American Transplant Congress
Leukopenia at the Time of Liver Transplantation: Medication Tolerance and Clinical Outcomes
E. Tiao¹, J. Casale¹, J. LaMattina², S. Hammad¹
¹Pharmacy, University of Maryland Medical Center, Baltimore, MD, ²Surgery, University of Maryland School of Medicine, Baltimore, MD
*Purpose: Leukopenia post-orthotopic liver transplant (OLT) is associated with an increased incidence of infection and mortality. Prior to OLT, leukopenia may suggest innate immunosuppression and…
2019 American Transplant Congress
Characteristics Associated with Immunosuppressant Adherence after Deceased Donor Kidney Transplant
A. R. Wilk¹, W. S. Cherikh¹, J. Maghirang¹, E. A. Witt², H. Kirkham², S. Boghani², N. Hira³, G. Pietradoni², D. K. Klassen¹
¹United Network for Organ Sharing, Richmond, VA, ²Walgreen Co, Deerfield, IL, ³AllianceRx Walgreens Prime, Orlando, FL
*Purpose: Without adherence to immunosuppressant (IS) medication, renal allografts will likely not last in transplant (TX) recipients, which may result in progressively worsened renal function…
2019 American Transplant Congress
Bortezomib Based Induction Therapy Decreases Delayed Graft Function in High Risk Kidney Transplantation
K. Mahendran¹, N. Koizumi², J. K. Melancon¹
¹Transplant Institute, The George Washington University, Washington, DC, ²Schar School of Policy and Government, George Mason University, Arlington, VA
*Purpose: Over 100,000 candidates await a kidney transplant on the national United Network for Organ Sharing (UNOS) waitlist. Among these candidates, one-third have pre-formed antibodies…
2019 American Transplant Congress
Utilizing Changing Patterns of T-cell Metabolism in Aging for Effective Immunosuppression
Y. Nian, T. Heinbokel, K. Minami, R. Maenosono, J. Iske, A. El Khal, S. G. Tullius
Transplant Surgery Research Lab, Brigham and Women’s Hospital, Boston, MA
*Purpose: Metabolic reprogramming has been identified as a critical regulator of immunity. Little is known on changes of T-cell metabolism in aging and how to…
2019 American Transplant Congress
A National Survey of Immunosuppression Strategies in Intestinal Transplantation
M. Segovia¹, T. Beduschi², J. Boike³, D. Farmer⁴, S. Horslen⁵, K. Iyer⁶, S. Jafri⁷, A. Langnas⁸, C. Matsumoto⁹, A. Mavis¹, G. Mazariegos¹⁰, S. Nagai⁷, J. O'Leary¹¹, Y. Patel¹, D. Sudan¹, N. Sulejmani⁷, B. Summers⁷, T. Schiano⁶
¹Duke, Durham, NC, ²Univ Miami, Miami, FL, ³NWU, Chicago, IL, ⁴UCLA, Los Angeles, CA, ⁵Seattle Child, Seattle, WA, ⁶Mt Sinai, NY, NY, ⁷Henry Ford, Detroit, MI, ⁸UNMC, Omaha, NE, ⁹Georgetown, Washington, DC, ¹⁰UPMC, Pittsburgh, PA, ¹¹Dallas VAMC, Dallas, TX
*Purpose: Review the management of immunosuppression (IS) for intestinal transplantation (IT) in the USA*Methods: A survey was created and sent via email to surgical directors…
2019 American Transplant Congress
Efficacy of Photobiomodulatory Therapy Combined with Short-Term Immunosuppressants Prolonged Allograft Survival in a Rodent Hind-Limb Model
Y. KUO¹, Y. Li¹, C. Chen¹, R. Chen1¹, G. Brandacher²
¹Division of Plastic Surgery, Department of Surgery,, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, ²Department of Plastic Surgery, VCA center, Johns Hopkins University, Baltimore, MD
*Purpose: Photobiomodulation has been applied for accelerating the skeletal muscle repair process. Our formal study demonstrated vitamin D could be involved in allograft survival and…
2019 American Transplant Congress
The Effect of a Novel Dosing Protocol for the De Novo Use of LCP Tacrolimus in Kidney Transplant Recipients Managed on a Steroid-Free Maintenance Immunosuppression Regimen
R. Wolff¹, A. Nasstrom¹, C. Borscheid¹, C. Martin¹, A. Temelie¹, R. Spong², D. Keys², T. B. Dunn³
¹School of Pharmacy, MHealth U of MN Medical Center-Fairview, Mpls, MN, ²Medicine, MHealth U of MN Medical Center-Fairview, Mpls, MN, ³Surgery, U of Pennsylvania, Phila, PA
*Purpose: It is not known if an extended release formulation of tacrolimus (LCPT, Envarsus XR®) can be successfully dosed to achieve an early therapeutic trough…
2019 American Transplant Congress
A Naturalistic Study of De Novo Extended-Release Tacrolimus Tablets vs. Tacrolimus Immediate-Release Capsules in Kidney Transplant Recipients
T. A. Horwedel¹, C. E. Carthon¹, S. E. January¹, A. Gharabagi¹, R. Delos Santos², J. C. Hagopian¹
¹Pharmacy, Barnes-Jewish Hospital, Saint Louis, MO, ²Nephrology, Washington University School of Medicine, Saint Louis, MO
*Purpose: Beginning in December 2015, our center instituted a protocol change moving to de novo use of LCPT. The objective of this study is to…